Esmolol
| Trade names |
Brevibloc |
|---|---|
| Clinical data | |
| Drug class |
Beta blocker |
| Routes of administration |
Intravenous |
| Dosage | |
| Pharmacodynamics | |
| Mechanism of action |
Beta-1 antagonism |
| Adverse effects |
Bradycardia, Hypotension |
| Pharmacokinetics | |
| Physical and chemical data | |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Esmolol is an ultrashort-acting selective β1-antagonist. It primarily decreases heart rate with less of an effect on blood pressure. [1]
Uses
Treat/prevent perioperative tachycardia and hypertension .
Opioid sparing anesthesia.[1]
Contraindications
Absolute contraindications
Precautions
While it is cardioselective at lower doses, use higher doses cautiously in patients with bronchospastic disease. [2]
Extreme caution should be used in patients with bradycardia, hypotension, greater than first degree heart block, cardiogenic shock or heart failure with reduced ejection fraction.[1] Avoid in patients who recently received a calcium channel blocker. [2]
Pharmacology
Pharmacodynamics
Mechanism of action
At normal doses it is a selective β1-antagonist, at higher doses it also inhibits β2 receptors in both bronchial and vascular smooth muscle. [1]
Adverse effects
Pharmacokinetics
Chemistry and formulation
History
References
- ↑ 1.0 1.1 1.2 1.3 Morgan & Mikhail's clinical anesthesiology. John F., IV Butterworth, David C. Mackey, John D. Wasnick (Seventh edition ed.). New York. 2022. ISBN 9781260473797. OCLC 1309921315.
|edition=has extra text (help)CS1 maint: others (link) - ↑ 2.0 2.1 "UpToDate - Esmolol: Drug information". www.uptodate.com. Retrieved 2022-12-21.